Japan’s GHIT ramps up fight against neglected tropical diseases
Writing for the Financial Times Health Report, Andrew Jack explores the recent activity of Japan's Global Health Innovative Technology Fund (GHIT). The Tokyo-based non-profit, helps facilitate partnerships between Japanese pharmaceutical companies and their commercial and academic counterparts around the world to tackle disease in low-income countries.
The article states that over the past 10 years several Japanese companies, through GHIT, have made progress in escalating work on neglected tropical diseases (NTDs). Notably, it states that two of these companies, Eisai and Takeda, have both risen through the Access to Medicine Index ranking since 2016.